Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRK-950 plus ramucirumab and paclitaxel in gastric or GEJ adenocarcinoma
jRCT2031230319Phase 2Recruiting
- Sponsor
- Toray Industries
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of TRK-950 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Toray Industries. Primary endpoint: Progression-free survival (Independent Central Review). Started Oct 2023; status: recruiting.
02
Drugs
TRK-950
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031230319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230319.